MAPT and Alzheimer disease: We used data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) research cohort to test whether CSF sTREM2 levels correlate with sTNFR2 among MCI and dementia subjects classified as AD, aggregated Aβ (A+) and aggregated tau (T+), according to the National Institute on Aging and Alzheimer's Association (NIA-AA) AT(N) framework (Jack et al., 2018) and whether CSF sTREM2 levels independent of sTNFR2 levels are associated with the AD biomarkers CSF Aβ42, t-tau, and p-tau.